Efficacy and safety of larotrectinib in patients with TRK fusion breast cancer

被引：0

作者：

Rosen, Ezra Y. ^{[1
]}

Italiano, Antoine ^{[2
]}

Juric, Dejan ^{[3
]}

Reeves, John A. ^{[4
]}

Dima, Laura ^{[5
]}

Brega, Nicoletta ^{[4
]}

Drilon, Alexander ^{[1
,6
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Inst Bergonie, Early Phase Trials Unit, Bordeaux, France

[3] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[4] Bayer HealthCare Pharmaceut, Whippany, NJ USA

[5] Bayer Consumer Care AG, Basel, Switzerland

[6] Weill Cornell Med Coll, New York, NY USA

来源：

CANCER RESEARCH | 2021年 / 81卷 / 04期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PS11-06

引用

页数：1

共 50 条

[21] Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma
Waguespack, Steven G.
Drilon, Alexander
Lin, Jessica J.
Brose, Marcia S.
McDermott, Ray
Almubarak, Mohammed
Bauman, Jessica
Casanova, Michela
Krishnamurthy, Anuradha
Kummar, Shivaani
Leyvraz, Serge
Oh, Do-Youn
Park, Keunchil
Sohal, Davendra
Sherman, Eric
Norenberg, Ricarda
Silvertown, Josh D.
Brega, Nicoletta
Hong, David S.
Cabanillas, Maria E.
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2022, 186 (06) : 631 - 643
[22] Efficacy of larotrectinib in TRK fusion cancer in adults and children
Blattmann, C.
Drilon, A.
Laetsch, T. W.
Kummar, S.
DuBois, S. G.
Lassen, U. N.
Demetri, G. D.
Nathenson, M.
Doebele, R. C.
Farago, A. F.
Pappo, A. S.
Turpin, B.
Dowlati, A.
Brose, M. S.
Mascarenhas, L.
Federman, N.
Berlin, J.
El-Deiry, W. S.
Baik, C.
Deeken, J.
Boni, V.
Nagasubramanian, R.
Taylor, M.
Rudzinski, E. R.
Meric-Bernstam, F.
Sohal, D. P. S.
Ma, P. C.
Raez, L. E.
Hechtman, J. F.
Benayed, R.
Ladanyi, M.
Tuch, B. B.
Ebata, K.
Cruickshank, S.
Ku, N. C.
Cox, M. C.
Hawkins, D. S.
Hong, D. S.
Hyman, D. M.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 154 - 155
[23] Efficacy and safety of larotrectinib in a pooled analysis of patients (Pts) with tropomyosin receptor kinase (TRK) fusion cancer
Drilon, A.
Shen, L.
van Tilburg, C.
Doz, F.
Tan, D. S. W.
Lin, J. J.
Kummar, S.
Lassen, U. N.
McDermott, R. S.
Dierselhuis, M. P.
Albert, C. M.
Nagasubramanian, R.
Watt, T.
Patil, T.
Burcoveanu, D-I.
Norenberg, R.
Brega, N.
Laetsch, T. W.
Xu, R-H.
Hong, D. S.
ANNALS OF ONCOLOGY, 2023, 34 : S470 - S470
[24] Updated efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer.
Drilon, Alexander E.
Lin, Jessica Jiyeong
Kummar, Shivaani
Tan, Daniel Shao-Weng
Patel, Jyoti D.
Lassen, Ulrik Niels
Leyvraz, Serge
Moreno, Victor
Rosen, Lee S.
Solomon, Benjamin Maurice
Yachnin, Jeffrey
Liu, Yongmei
Dai, Ming-Shen
Norenberg, Ricarda
Fellous, Marc Mardoche
Mussi, Chiara Erminia
Shen, Lin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[25] Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer.
Hong, David S.
Shen, Lin
van Tilburg, Cornelis Martinus
Tan, Daniel Shao-Weng
Kummar, Shivaani
Lin, Jessica Jiyeong
Doz, Francois P.
McDermott, Raymond S.
Albert, Catherine M.
Berlin, Jordan
Bielack, Stefan S.
Lassen, Ulrik Niels
Tahara, Makoto
Norenberg, Ricarda
Shurshalina, Anna
Fellous, Marc Mardoche
Nogai, Hendrik
Xu, Rui-hua
Laetsch, Theodore Willis
Drilon, Alexander E.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[26] Updated efficacy and safety of larotrectinib (laro) in patients (pts) with TRK fusion gastrointestinal (GI) cancer.
Shen, Lin
Andre, Thierry
Chung, Hyun Cheol Cheol
Deeken, John F.
Garralda, Elena
Italiano, Antoine
Leyvraz, Serge
Liu, Tianshu
Burcoveanu, Domnita-Ileana
Grugel, Robin
Mussi, Chiara E.
Xu, Rui-Hua
Hong, David S.
Drilon, Alexander E.
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 109 - 109
[27] Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase (TRK) Fusion-Positive Lung Cancer
Drilon, A.
Lin, J.
Lassen, U.
Leyvraz, S.
Liu, Y.
Patel, J.
Rosen, L.
Solomon, B.
Norenberg, R.
Dima, L.
Brega, N.
Shen, L.
Moreno, V.
Kummar, S.
Tan, D.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1125 - S1126
[28] Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer
Lin, Jessica Jiyeong
Tan, Daniel Shao-Weng
Kummar, Shivaani
Patel, Jyoti D.
Cermignani, Luciano
Dai, Ming-Shen
Lassen, Ulrik Niels
Leyvraz, Serge
Liu, Yongmei
Moreno, Victor
Rosen, Lee S.
Saada-Bouzid, Esma
Solomon, Benjamin Maurice
Xu, Rui-Hua
Yachnin, Jeffrey
Norenberg, Ricarda
Burcoveanu, Domnita-Ileana
Mussi, Chiara E.
Shen, Lin
Drilon, Alexander E.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[29] Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer
Rieke, D. T.
Lin, Iyeong J.
Tan, D. S.
Kummar, S.
Patel, J. D.
Cermignani, L.
Dai, M. -S.
Lassen, U. N.
Leyvraz, S.
Liu, Y.
Moreno, V.
Rosen, L.
Saada-Bouzid, E.
Solomon, B.
Xu, R. -H.
Yachnin, J.
Norenberg, R.
Burcoveanu, D. -I.
Mussi, C. E.
Shen, L.
Drilon, A.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 9 - 10
[30] Long-term efficacy and safety of larotrectinib in patients with TRK fusion-positive lung cancer.
Lin, Jessica Jiyeong
Kummar, Shivaani
Tan, Daniel Shao-Weng
Lassen, Ulrik Niels
Leyvraz, Serge
Liu, Yongmei
Moreno, Victor
Patel, Jyoti D.
Rosen, Lee S.
Solomon, Benjamin Maurice
Norenberg, Ricarda
Dima, Laura
Brega, Nicoletta
Shen, Lin
Drilon, Alexander E.
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

← 1 2 3 4 5 →